WYWensheng Yu
Wensheng Yu
*This is an algorithmically generated author record based on publicly available information.
Research Subjects
Research Interests
Wensheng Yu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Amy Doty
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publicationsCharles A. Lesburg
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publicationsDavid Jonathan Bennett
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publicationsDavid Sloman
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publicationsDerun Li
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publicationsHeidi Ferguson
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA
2 shared publications
Latest Publications
- 1 October 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 49, 128314
Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold
- 1 October 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 49, 128314
Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 47, 128214
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 47, 128214
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 47, 128168
Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 47, 128168
Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation